Ann: MYX announces patent lawsuit against Sun Pharmaceutical, page-12

First 12 Last

Share
Profile

Follow
stephencca

924 Posts.

336

28/07/24

17:49

Post #: 74951559
Share

Originally posted by roboshan: ↑

The patent challenge is all part of being the first company to file an Abbreviated New Drug Application (ANDA) for a generic version of Imvexxy. To be the first generic company to lodge an ANDA gives Sun Pharmaceuticals the jump on any other companies ANDA filings as it gains the first generic 6 months of exclusivity. The patents for Imvexxy still have 8 to 10 years to run so if the patents are proved to be valid then the Sun product cannot gain marketing approval for at least 8 years (unless they license it from Mayne). I would be quietly confident that when Mayne paid out $140m for purchase of the range of MD Therapeutics women's products they did extensive due diligence over the validity of the patents. This information will form the basis of Mayne's defense of the patent challenge (30 days to file the defense). Some of the follow on payments to MD Therapeutics such as royalties are based on the patents being held valid. It would not be uncommon for the owner of the innovator product to license out that product to the first generic competitor or launch their own generic product. This is all about protecting their longer term income stream against future generic competition. Despite the past stuff-ups with the purchase of or licensing of products I won't be losing any sleep over this one!

Expand

Thanks for that clarification. Its just to be expected. Its not anything out of the ordinary due to any negligence or incompetence of MYX.

MYX Price at posting: $4.38 Sentiment: Buy Disclosure: Held
1 Upvote

0 Great analysis

Reply

Top Stories

EXR

Elixir winds up QLD operations with five of six zones flowing gas; future production locked in

SS1

Sun Silver finds up to 524 g/t silver through pXRF readings in Nevada

AKO

Madagascar mining minister expresses support for Akora's Bekisopa iron ore project

LMS

Litchfield boosts its copper, base and precious metals footprint in the NT with acquisitions

RCE

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

There are more pages in this discussion • 8 more messages in this thread...

First 12 Last

Add MYX (ASX) to my watchlist

(20min delay)
Last $4.61		Change -0.010(0.22%)		Mkt cap ! $393.0M

Open	High	Low	Value	Volume
$4.60	$4.62	$4.54	$40.55K	8.877K

Buyers (Bids)

No.	Vol.	Price($)
1	12	$4.60

Sellers (Offers)

Price($)	Vol.	No.
$4.61	6	1

View Market Depth

No.	Vol.	Price($)
2	178	4.590
2	475	4.580
2	395	4.570
4	1476	4.560
2	481	4.550

Price($)	Vol.	No.
4.620	661	4
4.630	1144	5
4.640	7778	3
4.650	756	3
4.660	1755	4

Last trade - 10.36am 08/10/2024 (20 minute delay)

MYX (ASX) Chart

Ann: MYX announces patent lawsuit against Sun Pharmaceutical, page-12

Elixir winds up QLD operations with five of six zones flowing gas; future production locked in

Sun Silver finds up to 524 g/t silver through pXRF readings in Nevada

Madagascar mining minister expresses support for Akora's Bekisopa iron ore project

Litchfield boosts its copper, base and precious metals footprint in the NT with acquisitions

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

Ann: MYX announces patent lawsuit against Sun Pharmaceutical, page-12

Top Stories

Elixir winds up QLD operations with five of six zones flowing gas; future production locked in

Sun Silver finds up to 524 g/t silver through pXRF readings in Nevada

Madagascar mining minister expresses support for Akora's Bekisopa iron ore project

Litchfield boosts its copper, base and precious metals footprint in the NT with acquisitions

Recce eyes Indonesia for novel anti-infective as Indo-Aus ties grow stronger

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News